Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03187262 · ClinicalTrials.gov registry record · Phase 2
A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia
A Phase 2 study of Waldenström Macroglobulinemia, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
- 5
- Study locations
NCT03187262 is a Phase 2 study of Waldenström Macroglobulinemia that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 13 participants. The trial reports 5 study locations across 4 states.
The verdict
NCT03187262, a Phase 2 study of Waldenström Macroglobulinemia, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
- 5
- Study locations
Study Summary
This research study is studying Daratumumab as a possible treatment for Waldenström Macroglobulinemia.
Conditions Studied
Interventions
- DRUG Daratumumab
Study Locations (5)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic - Rochester
New York
- Memorial Sloan-Kettering Cancer Center - New York
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2017-11-27 |
| Est. Completion | 2021-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03187262
The ClinicalTrials.gov registry entry for NCT03187262 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Waldenström Macroglobulinemia appearing as the primary indexed condition, and to 1 intervention - of which Daratumumab is the first listed.
NCT03187262 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, Minnesota, New York.
Frequently Asked Questions
What is clinical trial NCT03187262 about?
NCT03187262 is a clinical study titled "A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia". This research study is studying Daratumumab as a possible treatment for Waldenström Macroglobulinemia.
What is the current status of trial NCT03187262?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2017-11-27. Estimated completion is 2021-12-31.
What conditions does trial NCT03187262 study?
This clinical trial studies the following conditions: Waldenström Macroglobulinemia.
What interventions are being tested in trial NCT03187262?
The interventions under investigation include: Daratumumab (DRUG).
Who is sponsoring clinical trial NCT03187262?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03187262 being conducted?
This trial has 5 study locations across Massachusetts, Minnesota, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Waldenström Macroglobulinemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.